@FierceMedDev: Becton Dickinson boost its quarterly dividend. Item | Follow @FierceMedDev
@MarkHFierce: J&J's $2.5B hip implant settlement offer is already beginning to generate some flack from patients. Story via NYT | Follow @MarkHFierce
> New Jersey's Tyber Medical closed a private placement equity round for an undisclosed amount. Plans call for using the money to accelerate marketing of its TyPEEK titanium plasma sprayed interbody fusion devices. Item
> Chinese medical device giant Mindray Medical ($MR) will hold its 2013 annual meeting at its Hong Kong offices on Dec. 17. Item
> Shareholders of Interlace Medical, which Hologic ($HOLX) snatched up in 2011, are suing the maker of women's health products for nearly $15 million in additional payments. Story
> Topera is touting results from a new independent multicenter clinical study showing that its 3-D mapping system helped improve long-term outcomes for atrial fibrillation patients. Item
> Bruker ($BRKR) won FDA clearance to market its new MALDI Biotyper CA System to identify gram-negative bacterial colonies cultured from human specimens. Item
Biotech News
@FierceBiotech: In our latest report, we feature the top women in the biotech industry. Report | Follow @FierceBiotech
@JohnCFierce: Sanofi might want to re-evaluate its cancer strategy about now. Iniparib and fedratinib both written off in '13. More | Follow @JohnCFierce
@DamianFierce: Pro-23andMe petition aims to protect "potentially life-saving diagnostic kits," thereby making the FDA's case. Petition | Follow @DamianFierce
@EmilyMFierce: Harvard study: 30% of all medical tests are probably unnecessary. More | Follow @EmilyMFierce
> Bayer's $2.4B bid to buy Algeta fits neatly with cancer drug strategy. Story
> Sanofi, Merrimack rack up third straight failure for lead cancer drug. Article
> BTG wins FDA OK for varicose vein treatment, projects $500M peak. Story
Pharma News
@FiercePharma: Monday's top story: Who leaked the scary Copaxone numbers? Teva intends to find out. Story | Follow @FiercePharma
@EricPFierce: Any who thinks women aren't controlling the destiny of biopharma would be wrong. Women in Biotech 2013 Report | Follow @EricPFierce
@CarlyHFierce: FDA withdraws restrictions on GSK diabetes drug Avandia - too little, too late? Story | Follow @CarlyHFierce
> Mylan, Biocon ready to roll out Herceptin biosimilar in India. Story
> FDA withdraws restrictions on GSK's Avandia. News
> Bayer bids $2.4B for Xofigo partner Algeta in drive for cancer growth. More
Pharma Manufacturing News
> JLL expects to buy more CMOs. Story
> Glaxo piles onto API expansion in Scotland. More
> PL Developments, Aaron combine expertise in OTC manufacturing. Article
> Ranbaxy ready to bail on vaccine manufacturing. More
> Bafna draws buyout interest for its European-approved manufacturing. News
Biotech Research News
> Eli Lilly, Project A.L.S. forge preclinical drug discovery pact. News
> Biota halts preclinical antibiotics program as antimicrobial resistance grows. Report
> New targets for Parkinson's revealed in gene network. Story
> Antibiotics may weaken body's response to cancer therapies. Article
> New York Stem Cell Foundation, NIH partner to study rare diseases. Story